What is AskGene Pharma?
AskGene Pharma, founded in 2012 and based in Los Angeles, California, is a biopharmaceutical company focused on the discovery and development of innovative antibody and fusion protein therapeutics. It is a pioneer in developing next-generation cytokine therapeutics through its proprietary SmartKine® cytokine prodrug platform. This platform is designed to enhance the developability of cytokines for treating oncology and inflammation indications. AskGene is actively advancing multiple therapeutic candidates through clinical and preclinical development, positioning itself at the forefront of novel drug discovery.
How much funding has AskGene Pharma raised?
AskGene Pharma has raised a total of $20.4M across 2 funding rounds:
Debt
$350K
Series A
$20M
Debt (2020): $350K with participation from PPP
Series A (2022): $20M led by Qiming Venture Partners and TF Capital
Key Investors in AskGene Pharma
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that focuses on investing in innovative companies across various sectors, including technology, healthcare, and artificial intelligence. They aim to support entrepreneurs by providing industry resources, strategic guidance, and fostering strong relationships with stakeholders.
TF Capital
TF Capital is a leading investor focused on partnering with early-stage innovators in the biotech sector. They provide comprehensive capital and strategic expertise, supporting promising biotech companies globally. With over $1 billion in assets under management and a diverse portfolio of more than 100 companies, TF Capital has successfully facilitated numerous IPOs and licensing deals.
PPP
Public-Private Partnership
What's next for AskGene Pharma?
With the recent major strategic investment, AskGene Pharma is poised for accelerated growth and the advancement of its therapeutic pipeline. The capital infusion is expected to fuel further research and development, potentially enabling the company to move its promising oncology and inflammation candidates into later-stage clinical trials. This strategic financing also suggests a strong validation of AskGene's SmartKine® platform by its investors, paving the way for potential partnerships, expanded clinical operations, and eventual commercialization efforts. The company's focus on novel cytokine therapeutics positions it to address significant unmet medical needs.
See full AskGene Pharma company page
